Special population considerations and regulatory affairs for clinical research

References

• Atuah KN, Hughes D, Pirmohamed M. Clinical pharmacology: Special safety considerations in drug development and pharmacovigilance. Drug Safety Int J Med Toxicol Drug Experience 2004;27:535–54
   PubMed Web of Science ®Google Scholar
• Taylor HA. Monitoring adherence to the NIH policy on the inclusion of women and minorities as subject in clinical research. Comprehensive report. 2011–2012. In: Committee NTI, ed. Silver Springs, MD, USA: United States Federal Agency; 2008
   Google Scholar
• FDA. Guidance for industry. United States Federal Agency; 2001. Available online at: www.fda.gov, accessed 9 Nov 2014
   Google Scholar
• GAO. Report to congressional requestors, women sufficiently represented in new drug testing, but fda oversight needs improvement. 2001. Available online at: www.gao.gov/new.items/d01754.pdf, accessed 9 Nov 2014
   Google Scholar
• FDA. FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using ambien cr. In: Safety Announcement 5-14-2013, Drug Safety Communication. Silver Springs, MD, USA: United States Federal Agency; 2013
   Google Scholar
• Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature 2014;509:282–3
   PubMed Web of Science ®Google Scholar
• NIH. Human clinical trials. 2001. Available online at: http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm, accessed 3 Nov 2014
   Google Scholar
• Rodriguez I, Kilborn MJ, Liu XK, et al. Drug-induced qt prolongation in women during the menstrual cycle. JAMA 2001;285:1322–6
   PubMed Web of Science ®Google Scholar
• El-Eraky H, Thomas SH. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. Br J Clin Pharmacol 2003;56:198–204
   PubMed Web of Science ®Google Scholar
• Du S, Itoh N, Askarinam S, et al. Xy sex chromosome complement, compared with xx, in the cns confers greater neurodegeneration during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2014;111:2806–11
   PubMed Web of Science ®Google Scholar
• Sadik R, Abrahamsson H, Stotzer PO. Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol 2003;38:36–42
   PubMed Web of Science ®Google Scholar
• Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology 1989;96:11–17
   PubMed Web of Science ®Google Scholar
• Singer AJ, Brandt LJ. Pathophysiology of the gastrointestinal tract during pregnancy. Am J Gastroenterol 1991;86:1695–712
   PubMed Web of Science ®Google Scholar
• Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gender Med 2009;6:152–67
   PubMedGoogle Scholar
• CDC. Births and natality. 2013. Available online at: http://www.cdc.gov/nchs/fastats/births.htm, accessed 1 November 2014
   Google Scholar
• Mazer-Amirshahi M, Samiee-Zafarghandy S, Gray G, van den Anker JN. Trends in pregnancy labeling and data quality for us-approved pharmaceuticals. Am J Obstet Gynecol 2014;211:690.e1–e11
   PubMed Web of Science ®Google Scholar
• Fine JS. Reproductive and perinatal principles. In: Nelson LS, editor. Goldfrank’s toxicologic emergencies. New York, NY: McGraw Hill; 2010. p423–46
   Google Scholar
• Mitchell AA, Gilboa SM, Werler MM, et al; National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol 2011;205:e51–8
   PubMed Web of Science ®Google Scholar
• Cleary KL, Roney K, Costantine M. Challenges of studying drugs in pregnancy for off-label indications: Pravastatin for preeclampsia prevention. Sem Perinatol 2014;38:523–7
   PubMed Web of Science ®Google Scholar
• Abduljalil K, Furness P, Johnson TN, et al. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: A database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2012;51:365–96
   PubMed Web of Science ®Google Scholar
• Zhao Y, Hebert MF, Venkataramanan R. Basic obstetric pharmacology. Sem Perinatol 2014;38:475–86
   PubMed Web of Science ®Google Scholar
• Ito T, Handa H. Deciphering the mystery of thalidomide teratogenicity. Congen Anom 2012;52:1–7
   PubMed Web of Science ®Google Scholar
• Taussig HB. Phocomelia and thalidomide. Am J Obstet Gynecol 1962;84:979
   PubMed Web of Science ®Google Scholar
• Antonucci R, Zaffanello M, Puxeddu E, et al. Use of non-steroidal anti-inflammatory drugs in pregnancy: Impact on the fetus and newborn. Curr Drug Metab 2012;13:474–90
   PubMed Web of Science ®Google Scholar
• Campbell SC, Spigarelli MG. Pharmacology and pharmacogenomics of neurological medications used in pregnancy. Clin Obstet Gynecol 2013;56:305–16
   PubMed Web of Science ®Google Scholar
• Lam J, Woodall KL, Solbeck P, et al. Codeine-related deaths: The role of pharmacogenetics and drug interactions. Forensic Sci Int 2014;239:50–6
   PubMed Web of Science ®Google Scholar
• Nechuta S, Mudd LM, Biery L, et al.; Michigan Alliance for the National Children’s Study. Attitudes of pregnant women towards participation in perinatal epidemiological research. Paediat Perinat Epidemiol 2009;23:424–30
   PubMed Web of Science ®Google Scholar
• Rodger MA, Makropoulos D, Walker M, et al. Participation of pregnant women in clinical trials: Will they participate and why? Am J Perinatol 2003;20:69–76
   PubMed Web of Science ®Google Scholar
• FDA. Womens health research. Office of Women’s Health (OWH). 1994. Available online at: http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch, accessed 1 Nov 2014
   Google Scholar
• FDA. Pregnancy exposure registries. 2011. Available online at: http://www.fda.gov/scienceresearch/specialtopics/womenshealthresearch/ucm251314.htm, accessed 1 Nov 2014
   Google Scholar
• Shirkey H. Therapeutic orphans. J Pediat 1968;72:119–20
   PubMed Web of Science ®Google Scholar
• American College of Clinical Pharmacy, Cheang KI, Ott C, et al. Research in women and special populations. Pharmacotherapy 2008;28:93E–113E
   Google Scholar
• Ginsberg G, Hattis D, Sonawane B, et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci Offic J Soc Toxicol 2002;66:185–200
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E, Choonara I, eds. Paediatric clinical pharmacology. New York: CRC Press; Taylor & Francis; 2006
   Google Scholar
• Pineiro-Carrero VM, Pineiro EO. Liver. Pediatrics 2004;113:1097–106
   PubMed Web of Science ®Google Scholar
• Kennedy MJ, Davis DA, Smith N, et al. Reduced activities of cytochrome p450 1a2 and xanthine oxidase in children with growth hormone deficiency. Clin Pharmacol Ther 2008;84:674–8
   PubMed Web of Science ®Google Scholar
• Tayman C, Rayyan M, Allegaert K. Neonatal pharmacology: Extensive interindividual variability despite limited size. J Pediat Pharmacol Ther: JPPT: Offic L PPAG 2011;16:170–84
   PubMedGoogle Scholar
• Rocchi F, Tomasi P. The development of medicines for children. Part of a series on pediatric pharmacology, guest edited by gianvincenzo zuccotti, emilio clementi, and massimo molteni. Pharmacol Res Offic J It Pharmacol Soc 2011;64:169–75
   PubMed Web of Science ®Google Scholar
• Marsot A, Boulamery A, Bruguerolle B, Simon N. Population pharmacokinetic analysis during the first 2 years of life: An overview. Clin Pharmacokin 2012;51:787–98
   PubMed Web of Science ®Google Scholar
• Millership JS. Microassay of drugs and modern measurement techniques. Paediatr Anaesth 2011;21:197–205
   PubMed Web of Science ®Google Scholar
• Stolk LML, Degraeuwe PLJ, Nieman FHM, et al. Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit 2002;24:527–31
   PubMed Web of Science ®Google Scholar
• Shevchuk YM, Taylor DM. Aminoglycoside volume of distribution in pediatric patients. DICP, Ann Pharmacother 1990;24:273–6
   PubMedGoogle Scholar
• Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokin 1990;19:280–318
   PubMed Web of Science ®Google Scholar
• Friis-Hansen B. Water distribution in the foetus and newborn infant. Acta Paediatr Scand Suppl 1983;305:7–11
   PubMedGoogle Scholar
• Butte NF, Hopkinson JM, Wong WW, et al. Body composition during the first 2 years of life: An updated reference. Pediat Res 2000;47:578–85
   PubMed Web of Science ®Google Scholar
• Bauer LA. Clinical pharmacokinetics handbook. New York: McGraw-Hill; 2006
   Google Scholar
• Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (part 2). Clin Pharmacokin 1988;14:261–86
   PubMed Web of Science ®Google Scholar
• van den Anker JN. Pharmacokinetics and renal function in preterm infants. Acta Paediatr 1996;85:1393–9
   PubMed Web of Science ®Google Scholar
• Miall LS, Henderson MJ, Turner AJ, et al. Plasma creatinine rises dramatically in the first 48 hours of life in preterm infants. Pediatrics 1999;104:e76
   PubMed Web of Science ®Google Scholar
• Wahl EF, Lahdes-Vasama TT, Churchill BM. Estimation of glomerular filtration rate and bladder capacity: The effect of muturation, ageing, gender and size. BJU Int 2003;91:255–62
   PubMed Web of Science ®Google Scholar
• Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984;104:849–54
   PubMed Web of Science ®Google Scholar
• Coulthard MG. Maturation of glomerular filtration in preterm and mature babies. Early Human Dev 1985;11:281–92
   PubMed Web of Science ®Google Scholar
• Assael B, Rusconi F. Aminoglycoside antibotics. In: Yaffe SJ, Aranda JV, eds. Pediatric pharmacology: Therapeutic principles in practice. Philadelphia, PA: Saunders Company; 1992. p244–9
   Google Scholar
• Prober CG, Stevenson DK, Benitz WE. The use of antibiotics in neonates weighing less than 1200 grams. Pediatr Infect Dis J 1990;9:111–21
   PubMed Web of Science ®Google Scholar
• Arant BS Jr. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr 1978;92:705–12
   PubMed Web of Science ®Google Scholar
• Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003;55:667–86
   PubMed Web of Science ®Google Scholar
• Weber W, Kewitz G, Rost KL, et al. Population kinetics of gentamicin in neonates. Eur J Clin Pharmacol 1993;44:S23–5
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E. Drug policy in Europe research and funding in neonates: Current challenges, future perspectives, new opportunities. Early Hum Dev 2011;87:S27–30
   PubMed Web of Science ®Google Scholar
• US Department of Health & Human Services Regulations. 2014. Available online at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=7.55, accessed 5 Nov 2014
   Google Scholar
• United States Federal Agency. 21CFR § 50.55: Protection of human subjects subpart d - additional safeguards for children in clinical investigations, requirements for permission by parents or guardians and for assent by children. Washington, DC: U.S. Department of Health and Human Services. Revised 2014. Available online at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50&showFR=1&subpartNode=21:1.0.1.1.20.4, accessed 13 Nov 2014
   Google Scholar
• United States Federal Agency. 45CFR § 46.405: Protection of human subjects subpart d – additional protections for children involved as subjects in research, research involving greater than minimal risk but presenting the prospect of direct benefit to the individual subjects. Washington, DC: U.S. Department of Health and Human Services. 2009. Available online at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html, accessed 13 Nov 2014
   Google Scholar
• United States Federal Agency. 21CFR § 50.52: Protection of human subjects subpart d – additional safeguards for children in clinical investigations, clinical investigations involving greater than minimal risk but presenting the prospect of direct benefit to individual subjects. Washington, DC: U.S. Department of Health and Human Services. Revised 2014. Available online at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50&showFR=1&subpartNode=21:1.0.1.1.20.4, accessed 13 Nov 2014
   Google Scholar
• United States Federal Agency. 45CFR § 46.406: Protection of human subjects subpart d – additional protections for children involved as subjects in research, research involving greater than minimal risk and no prospect of direct benefit to individual subjects, but likely to yield generalizable knowledge about the subject’s disorder or condition. Washington, DC: U.S. Department of Health and Human Services. 2009. Available online at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html, accessed 13 Nov 2014
   Google Scholar
• United States Federal Agency. 21CFR § 50.53: Protection of human subjects, part d – additional safeguards for children in clinical investigations, clinical investigations involving greater than minimal risk and no prospect of direct benefit to individual subjects, but likely to yield generalizable knowledge about the subjects' disorder or condition. Washington, DC: U.S. Department of Health and Human Services. Revised 2014. Available online at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50&showFR=1&subpartNode=21:1.0.1.1.20.4, accessed 13 Nov 2014
   Google Scholar
• United States Federal Agency. 45CFR § 46.407: Protection of human subjects subpart d – additional protections for children involved as subjects in research, research not otherwise approvable which presents an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children. Washington, DC: U.S. Department of Health and Human Services. 2009. Available online at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html, accessed 13 Nov 2014
   Google Scholar
• United States Federal Agency. 21CFR § 50.54: Protection of human subjects, part d – additional safeguards for children in clinical investigations, clinical investigations not otherwise approvable that present an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children. Bethesda, MD, USA: Department of Health and Human Services. Revised 2014. Available online at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50&showFR=1&subpartNode=21:1.0.1.1.20.4, accessed 13 Nov 2014
   Google Scholar
• NICHD/NIH. Best pharmaceuticals for children act. 2002. Available online at: http://bpca.nichd.nih.gov/about/Pages/Index.aspx, accessed 6 Nov 2014
   Google Scholar
• US Census Bureau. The next four decades the older population in the United States: 2010 to 2050. May 2010. Available online at: www.census.gov/…/2010pubs/p25-1138.pdf, accessed 11 Nov 2014
   Google Scholar
• Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. Prescription drug data for 2007–2008. NCHS Data Brief 2010;42:1–8
   PubMedGoogle Scholar
• Pretorius RW, Gataric G, Swedlund SK, Miller JR. Reducing the risk of adverse drug events in older adults. Am Fam Physician 2013;87:331–6
   PubMed Web of Science ®Google Scholar
• Gidal BE. Drug absorption in the elderly: Biopharmaceutical considerations for the antiepileptic drugs. Epilepsy Res 2006;68:S65–9
   PubMed Web of Science ®Google Scholar
• Turnheim K. When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003;38:843–53
   PubMed Web of Science ®Google Scholar
• Chau DL, Walker V, Pai L, Cho LM. Opiates and elderly: Use and side effects. Clin Intervent Aging 2008;3:273–8
   PubMed Web of Science ®Google Scholar
• Schmucker DL. Liver function and phase i drug metabolism in the elderly: A paradox. Drugs Aging 2001;18:837–51
   PubMed Web of Science ®Google Scholar
• Robertson DR, Waller DG, Renwick AG, George CF. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988;25:297–305
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41:67–76
   PubMed Web of Science ®Google Scholar
• Denson AC, Mahipal A. Participation of the elderly population in clinical trials: Barriers and solutions. Cancer Cont J Moffitt Cancer Center 2014;21:209–14
   PubMed Web of Science ®Google Scholar
• Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: Clinical, research, and policy implications of a core geriatric concept. J Am Geriat Soc 2007;55:780–91
   PubMed Web of Science ®Google Scholar
• GAO-07-47R: Elderly persons in clinical drug trials. 2007. Available online at: http://www.gao.gov/products/GAO-07-47R, accessed 9 Nov 2014
   Google Scholar
• United States Federal Agency. 45CFR § 46.102 Protection of human subjects, subpart a – basic hhs policy for protection of human research subjects, definitions. Washington, DC: U.S. Department of Health and Human Services. 2009. Available online at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html, accessed 13 Nov 2014
   Google Scholar
• United States Federal Agency. 21CFR § 50.3: Protection of human subjects, part a – general provisions, definitions. Washington, DC: U.S. Department of Health and Human Services. Revised 2014. Available online at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html, accessed 13 Nov 2014
   Google Scholar
• FDA. Animal rule of 2014 is a draft guidance for industry for product development. 2014. Available online at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf, accessed 15 Nov 2014
   Google Scholar
• Carter AM. Animal models of human placentation—a review. Placenta 2007;28:S41–7
   PubMed Web of Science ®Google Scholar
• Peng L, Cui JY, Yoo B, et al. Rna-sequencing quantification of hepatic ontogeny of phase-i enzymes in mice. Drug Metab Disposit Biol Fate Chem 2013;41:2175–86
   PubMed Web of Science ®Google Scholar
• Barroso M, Dargouge O, Lechner MC. Expression of a constitutive form of cytochrome p450 during rat-liver development and sexual maturation. Eur J Biochem FEBS 1988;172:363–9
   PubMedGoogle Scholar
• Pretheeban M, Hammond G, Bandiera S, et al. Ontogenesis of phase i hepatic drug metabolic enzymes in sheep. Reprod Fertil Dev 2012;24:425–37
   PubMed Web of Science ®Google Scholar
• Roth WJ, Kissinger CB, McCain RR, et al. Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing. AAPS J 2013;15:763–74
   PubMed Web of Science ®Google Scholar
• Gill D. Ethical principles and operational guidelines for good clinical practice in paediatric research. Recommendations of the ethics working group of the confederation of European specialists in paediatrics (cesp). Eur J Pediatr 2004;163:53–7
   PubMed Web of Science ®Google Scholar
• Allegaert K, van de Velde M, van den Anker J. Neonatal clinical pharmacology. Paediat Anaesth 2014;24:30–8
   PubMed Web of Science ®Google Scholar
• Kawamura A, Graham J, Mushtaq A, et al. Eukaryotic arylamine n-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem Pharmacol 2005;69:347–59
   PubMed Web of Science ®Google Scholar
• Rocchi F, Tomasi P. The development of medicines for children. Part of a series on pediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacol Res Offic J It Pharmacol Soc 2011;64:169–75
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999;43:1549–55
   PubMed Web of Science ®Google Scholar
• Winter ME. Basic clinical pharmacokietics. Baltimore, MD: Lippincott Williams & Wilkins; 2004
   Google Scholar